Jacques Genest jr. médecin canadien
Genest, Jacques, 1957-
VIAF ID: 28735662 (Personal)
Permalink: http://viaf.org/viaf/28735662
Preferred Forms
- 100 1 _ ‡a Genest, Jacques ‡d 1957-
- 100 1 0 ‡a Genest, Jacques, ‡d 1957-
-
- 100 0 _ ‡a Jacques Genest jr. ‡c médecin canadien
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus | |
The Essential Role of Primary Caregiver in Early Detection of Familial Hypercholesterolemia and Cardiovascular Prevention. | |
Estrogen-associated severe hypertriglyceridemia with pancreatitis. | |
Exome sequencing in suspected monogenic dyslipidemias | |
Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects | |
Functional mutations of the ABCA1 gene in subjects of French-Canadian descent with HDL deficiency | |
Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice. | |
Genetic lipoprotein disorders and coronary atherosclerosis | |
Genetics of cholesterol efflux | |
The genetics of dilated cardiomyopathy: a prioritized candidate gene study of LMNA, TNNT2, TCAP, and PLN | |
Guide du médecin pour le traitement des dyslipoprotéinémies. CIP. | |
HDL, Atherosclerosis, and Emerging Therapies | |
HDL-C: clinical equipoise and vascular endothelial function | |
HDL cholesterol and ASCVD risk stratification: A debate. | |
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial | |
The HDL proteome in acute coronary syndromes shifts to an inflammatory profile | |
High-density lipoproteins: multifunctional vanguards of the cardiovascular system | |
Homocysteine lowering with folic acid and B vitamins in vascular disease | |
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). | |
Identification of a novel human cellular HDL biosynthesis defect. | |
Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis | |
Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. | |
Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B. | |
The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. | |
Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification | |
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol | |
Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis | |
Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). | |
Molecular interactions between apoE and ABCA1: impact on apoE lipidation | |
Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. | |
The new dyslipidemia guidelines: what is the debate? | |
New insights into the biogenesis of human high-density lipoproteins | |
Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro | |
Novel Approaches for HDL-Directed Therapies. | |
Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary | |
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) | |
Pathological significance of lipoprotein(a) in aortic valve stenosis. | |
Physicians' guide to the management of lipoprotein disorders, c1990: | |
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies | |
Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. | |
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS) | |
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease | |
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update | |
Reducing the burden of disease and death from familial hypercholesterolemia: a call to action | |
Reducing Vascular Calcification by Anti-IL-1β Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia | |
Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype | |
Residual macrovascular risk in 2013: what have we learned? | |
Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: a systematic review and meta-analysis | |
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions | |
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating R | |
Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial | |
RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo | |
Secretory vesicular transport from the Golgi is altered during ATP-binding cassette protein A1 (ABCA1)-mediated cholesterol efflux | |
Severe hyperhomocysteinemia due to cystathionine β-synthase deficiency, and Factor V Leiden mutation in a patient with recurrent venous thrombosis | |
Simplified Canadian Definition for Familial Hypercholesterolemia | |
Smashing Low-Density Lipoprotein Levels and Preventing Coronary Allograft Vasculopathy: One Heart Transplant Patient at a Time. | |
Sphingomyelin phosphodiesterase-1 (SMPD1) coding variants do not contribute to low levels of high-density lipoprotein cholesterol | |
Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO). | |
Structural and functional properties of human plasma high density-sized lipoprotein containing only apoE particles | |
Structural modification of plasma HDL by phospholipids promotes efficient ABCA1-mediated cholesterol release | |
Surgical strategies for severe calcification of the aorta (porcelain aorta) in two patients with homozygous familial hypercholesterolemia | |
Treatment options for low high-density lipoproteins | |
Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype | |
The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification | |
WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels | |
The WWOX gene modulates high-density lipoprotein and lipid metabolism |